Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2026-06-05 @ 10:15 AM
Study NCT ID:
NCT01711151
Status:
UNKNOWN
Last Update Posted:
2012-10-22
First Post:
2012-10-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Interstitial Lung Disease Questionnaire
Sponsor:
University of East Anglia
Organization:
Study Overview
Official Title:
Questionnaire Study for Patients With Interstitial Lung Disease
Status:
UNKNOWN
Status Verified Date:
2012-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1. To evaluate the health status of patients with Interstitial Lung Disease (ILD), and how this varies between subgroups of ILD.
2. To investigate the prevalence of symptoms, anxiety, depression, and sleep-disordered breathing within ILD patient population.
3. To assess the economic impact of ILD.
4. To understand how self-aware ILD patients are regarding their treatment/management.
5. To compare the demographic details, including smoking status and occupational history, of patients with interstitial lung disease
2. To investigate the prevalence of symptoms, anxiety, depression, and sleep-disordered breathing within ILD patient population.
3. To assess the economic impact of ILD.
4. To understand how self-aware ILD patients are regarding their treatment/management.
5. To compare the demographic details, including smoking status and occupational history, of patients with interstitial lung disease
Detailed Description:
Primary endpoint
• Health status in the target populations, as determined by the K-BILD questionnaire.
Secondary endpoints -
* Severity of dyspnoea suffered by patients
* Prevalence of anxiety and depression
* Prevalence of sleep-disordered breathing symptoms
* Degree of self-awareness displayed by patients
* The costs associated with ILD from a patient and healthcare perspective.
* Demographic details
• Health status in the target populations, as determined by the K-BILD questionnaire.
Secondary endpoints -
* Severity of dyspnoea suffered by patients
* Prevalence of anxiety and depression
* Prevalence of sleep-disordered breathing symptoms
* Degree of self-awareness displayed by patients
* The costs associated with ILD from a patient and healthcare perspective.
* Demographic details
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| UEAILDQUEST | OTHER | University of East Anglia | View |